Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Cardiovascular
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
CK-4021586Phase 21 trial
Active Trials
NCT06793371Recruiting60Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2025
2026
CytokineticsCK-4021586

Clinical Trials (1)

Total enrollment: 60 patients across 1 trials

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Start: Feb 2025Est. completion: Sep 202660 patients
Phase 2Recruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 60 patients
1 companies competing in this space